Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZymoGenetics Experiences a Biotech Disconnect

This article was originally published in RPM Report

Executive Summary

It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.
Advertisement

Related Content

Advertising Citations Reach Record High: Another Way To Regulate Pharma?
Biologics Are Ray Of Light In Dim Outlook For FDA’s 2008 Approval Totals
FDA Challenges ZymoGenetics' Safety Claims
ZymoGenetics' Biotech Disconnect
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
NME Goal Dates Sparse In Late 2007: Third Year Of Low NME Count Likely
FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17
Novo-ZymoGenetics: The Next Roche-Genentech?
ZymoGenetics Allies With Bayer To Blitz U.S. Hospital Market With rhThrombin
Deal Early, Less Often: ZymoGenetics' Broad Deal with Serono

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS080419

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel